Jean-Jacques Lebrun

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Combination Therapy

Tyrosine Kinase

Top Venues

NPJ precision oncology

Breast cancer research : BCR

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Amina Jamal Laham, Raafat El-Awady, Maha Saber Ayad, Ni Wang, Gang Yan, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. NPJ precision oncology 8 (1) (2024)
Gang Yan, Meiou Dai, Sophie Poulet, Ni Wang, Julien Boudreault, Girija Daliah, Suhad Ali, Jean-Jacques Lebrun
Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance. Oncogenesis 12 (1) (2023)
Jun Tian, Vivian Wang, Ni Wang, Baharak Khadang, Julien Boudreault, Khldoun Bakdounes, Suhad Ali, Jean-Jacques Lebrun
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast cancer research : BCR 23 (1) (2021)
Gang Yan, Meiou Dai, Chenjing Zhang, Sophie Poulet, Alaa Moamer, Ni Wang, Julien Boudreault, Suhad Ali, Jean-Jacques Lebrun
TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity. Oncogenesis 10 (3) (2021)
Meiou Dai, Gang Yan, Ni Wang, Girija Daliah, Ashlin M Edick, Sophie Poulet, Julien Boudreault, Suhad Ali, Sergio A Burgos, Jean-Jacques Lebrun
In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nature communications 12 (1) (2021)